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SUMMARY
Constitutive activation of MEK-ERK signaling is often found in melanomas. Here, we identify
a mechanism that links ERK with JNK signaling in human melanoma. Constitutively active ERK
increases c-Jun transcription and stability, which are mediated by CREB and GSK3, respectively.
Subsequently, c-Jun increases transcription of target genes, including RACK1, an adaptor protein
that enables PKC to phosphorylate and enhance JNK activity, enforcing a feed-forward mechanism
of the JNK-Jun pathway. Activated c-Jun is also responsible for elevated cyclin D1 expression, which
is frequently overexpressed in human melanoma. Our data reveal that, in human melanoma, the re-
wired ERK signaling pathway upregulates JNK and activates the c-Jun oncogene and its downstream
targets, including RACK1 and cyclin D1.INTRODUCTION
Current understanding of changes commonly seen in
human melanoma suggests that this tumor type may
serve as a paradigm of signaling cascades that undergo
a rewiring program. A large percentage of melanomas
harbor superactive kinases, primarily of the mitogen-acti-
vated protein kinase (MAPK) family, as a result of activat-
ing mutations inBRAF orNRAS genes (Davies et al., 2002;
Pollock and Meltzer, 2002; Gorden et al., 2003). Normally,
kinases of the MAPK family control a diverse array of cel-
lular functions such as gene expression, the inflammatory
response, differentiation, the cell cycle, cell proliferation,
and apoptosis (Weston and Davis, 2002). The extracellu-
lar-signal-regulated kinase (ERK), which is normally acti-
vated primarily by mitogens (Johnson and Lapadat,
2002), has been implicated in differentiation, senescence,
and survival. Mutations in BRAF or NRAS genes, foundin >70% of intermittently sun-exposed melanomas
(Maldonado et al., 2003), cause superactivation of ERK,
which has been implicated in activation of MMP1 and
MITF (Molina et al., 2005; Park et al., 2004), although the
precise mechanism linking ERK and the downstream
targets remains, in many cases, elusive. In the present
study, we demonstrate that highly active ERK affects the
degree of c-Jun NH2-terminal kinase (JNK) activity. As
a result, it upregulates the c-Jun oncogene and conse-
quently the c-Jun target cyclin D1, which is frequently
upregulated in human melanoma.
JNK, which is among the major subgroups of MAPK, is
activated primarily by inflammatory cytokines and envi-
ronmental stress (Karin, 1995; Weston and Davis, 2002).
These stimuli induce JNK phosphorylation on Thr183
and Tyr185 residues by the dual specific kinases MKK4
and MKK7 (Davis, 2000). Among key JNK substrates is
the transcription factor c-Jun. Phosphorylation by JNKSIGNIFICANCE
Although constitutively active ERK-MAPK signaling has been found in a large fraction of humanmelanoma tumors,
how this pathway contributes to melanoma development remains largely elusive. Here, we reveal the blueprint for
rewiring of key signal transduction pathways in melanoma. In this rewiring program, constitutively active ERK
affects the c-Jun oncogene, its upstream kinase JNK, and its downstream targets RACK1 and cyclin D1. Under-
standing how key signaling pathways are rewired in melanoma offers new potential targets for therapy of this
tumor type.Cancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc. 447
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ERK-JNK Crosstalk in Melanomaenables c-Jun’s cooperation with members of the b-ZIP
family, including c-Fos and ATF2, resulting in concomitant
activation of a wide set of substrates that control the cell
cycle as well as cell proliferation, differentiation, and death
(Vogt, 2001; Shaulian and Karin, 2002). c-Jun cooperates
with both cellular and viral oncogenes (e.g., mutant Ras) to
mediate transformation of cells in culture (Johnson et al.,
1996) and tumor development in animal models (Eferl
et al., 2003), activities consistent with its deregulation in
various human tumors (Mathas et al., 2002). As a protein
that plays a key role in cell growth and transformation,
c-Jun is tightly regulated at the levels of expression and
activity. Among key factors in c-Jun regulation is its phos-
phorylation, which affects its stability and activity (Morton
et al., 2003; Laine and Ronai, 2005). Phosphorylation of
c-Jun at Ser63, Ser73, Thr91, and Thr93, primarily medi-
ated by JNK, is required for its transcriptional activity
(Minden et al., 1994) and protects c-Jun from ubiquitina-
tion and subsequent degradation (Fuchs et al., 1996).
Conversely, phosphorylation of c-Jun on Thr239 and
Ser243 targets it for ubiquitination and subsequent degra-
dation by Fbw7 (Wei et al., 2005), a modification that is
important in c-Jun’s ability to elicit its oncogenic activity.
Here we demonstrate that ERK utilizes two distinct
mechanisms to upregulate c-Jun expression, which, in
turn, further increase JNK signaling and induce high levels
of cyclin D1 expression.
The degree of JNK activation in response to diverse
stimuli can be augmented by its phosphorylation via pro-
tein kinase C (Lopez-Bergami et al., 2005a; Liu et al.,
2006). JNK activation by PKC is required for its maximal
induction by diverse stimuli including cytokines (e.g.,
TNFa) and external stress (e.g., UV-irradiation). PKC’s
effect on JNK requires RACK1, a 7 WD40 repeat scaffold
implicated in PKC and Src signaling (Ron et al., 1994).
Changes in activity or levels of the PKC-RACK1 module
affect the magnitude of JNK activation (Lopez-Bergami
et al., 2005a). Thus, changes in RACK1 expression are
expected to affect the degree of JNK activity. Elevated
RACK1 expression was observed in non-small-cell lung
carcinoma (Berns et al., 2000), colon carcinoma (Berns
et al., 2000; Saito et al., 2002), andmelanoma (Lopez-Ber-
gami et al., 2005a). The link between RACK1 and JNK is
also expected to play a key role in tumorigenicity, as inhi-
bition of RACK1 expression sensitizes melanoma cells to
treatment and reduces their tumorigenicity in a xenograft
tumor model (Lopez-Bergami et al., 2005a). Here, we
demonstrate that ERK upregulates JNK activity via its
effect on c-Jun and concomitant c-Jun activation of
RACK1 transcription. RACK1, in turn, increases the de-
gree of JNK activation by PKC, resulting in further activa-
tion of c-Jun and its downstream transcriptional targets,
including cyclin D1.
Cyclin D1 is a 34 kDa nuclear protein coded by the
CCND1 gene, which is located at 11q13. Cyclin D1 is an
important positive regulator of the G1-S cell-cycle transi-
tion, which is achieved through its binding and activation
of its kinase partner’s cdk4/6, contributing tophosphoryla-
tion and inactivation of pRb, blocking its growth-inhibitory448 Cancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc.activity and promoting release of bound E2F, leading to
cell-cycle progression (Bartek et al., 1996). Amplification
of CCND1was found in primary melanomas and metasta-
ses to varying degrees (Utikal et al., 2005), suggesting
a role for the CCND1 gene in the pathogenesis of mela-
noma. Whereas increased copy number of the CCND1
gene is associated with overexpression of cyclin D1, over
25% of melanomas that overexpressed cyclin D1 have
a normal copy number of the CCND1 gene (Sauter et al.,
2002), suggesting that expression levels of cyclin D1 are
modulated by mechanisms other than gene amplification.
Expression of cyclin D1 has been demonstrated at consti-
tutively high levels in melanoma cell lines (Bartek et al.,
1993), as well as in melanoma metastases (Maelandsmo
et al., 1996; Erricoet al., 2003;Sauter et al., 2002), suggest-
ing that it has an oncogenic role in melanoma patho-
genesis. The present studies provide mechanistic under-
standing of upregulation of c-Jun and consequently its
target genes, including cyclin D1 in melanoma, as part of
a rewiring of signaling cascades involving ERK and JNK.
RESULTS
The Activated MAPK Pathway Is Responsible
for Elevated c-Jun Levels in Melanoma
We recently demonstrated that JNK activation can be
augmented upon its phosphorylation by PKC, which
requires the adaptor protein RACK1 (Lopez-Bergami
et al., 2005a). Since the mechanism underlying upregula-
tion of PKC or RACK1 is not known, we explored the
possible effects of the ERK signaling pathway, which is
notoriously upregulated in this tumor type, on RACK1
expression. Analysis of melanoma cell lines revealed
that those expressing high levels of RACK1 contain higher
levels of active PKCa/b, ERK, and JNK, as reflected by
their phosphorylation on residues required for their activ-
ity (Figure 1A). Since active ERK is also associated with
increased levels of c-Jun (Figure 1A), we assessed the
possible impact of ERK on c-Jun expression.
To directly assess a causative link between ERK and c-
Jun, we used three inhibitors known to affect B-RAF and
MEK,major components in this pathway, which is deregu-
lated in melanoma. Treatment of melanoma Lu1205 cells
with CHR-265, a B-RAF inhibitor, reduced c-Jun levels
(Figure 1B). This effect was mediated by the MEK/ERK
pathway since a similar decrease was observed following
treatment with the specific MEK inhibitors U0126 and
PD98059 (Figure 1C). The effect of ERK on c-Jun expres-
sion was specific to melanoma cells, as it was not seen in
HEK293T cells (see Figure S1 in the Supplemental Data
available with this article online) or in human melanocytes
(Figure S2) in which MEK/ERK are not constitutively upre-
gulated. The possibility that changes in c-Jun expression
following MEK/ERK inhibition were due to altered cell-
cycle distribution was ruled out (Figure S3). These data
suggest that ERK signaling plays a central role in upregu-
lation of c-Jun expression in human melanoma cells in
which this signaling cascade is constitutively active. We
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ERK’s effect on c-Jun expression and activity.
ERK Regulates c-Jun Stability
To assess themechanism bywhich ERK sustains elevated
levels of c-Jun, we tested possible effects of ERK inhibi-
tion on transcription and stability of c-Jun. Addition of ac-
tinomycin D or PD98059 caused a noticeable decrease in
the level of c-Jun expression. However, after a 2 hr treat-
ment, theMEK/ERK inhibitor decreased c-Jun levels more
efficiently than actinomycin D (Figure 2A). These differ-
ences implied the possible involvement of both transcrip-
tional and posttranscriptional mechanisms in ERK’s regu-
lation of c-Jun. Since c-Jun is an unstable protein that is
regulated by several ubiquitin ligases (reviewed in Laine
Figure 1. ERK Signaling Affects c-Jun Expression
(A) Levels of P-ERK, P-JNK, and proteins relevant to the PKC/JNK
pathway in melanoma cell lines. Protein extracts (40 mg) from mela-
noma cell lines were analyzed by western blots using the indicated
antibodies. Human melanocytes (HuMel) were used as a control.
a-Tubulin reveals equal loading.
(B) Inhibition of B-Raf reduces c-Jun levels. Lu1205 cells were treated
with 300 nM CHR-265 for 6 hr and 24 hr. Protein samples were
analyzed by western blots using the indicated antibodies. a-Tubulin
reveals equal loading.
(C) Inhibition of the MEK/ERK pathway reduces c-Jun levels. A375
cells were treated with 50 mM PD98059 and 20 mM U0126 for 24 h.
Protein samples were analyzed by western blots using the indicated
antibodies.and Ronai, 2005), we first tested the possible effect of
ERK on c-Jun stability. Proteasome inhibitors attenuated
the effect of the ERK inhibitors and further increased the
level of c-Jun expression (Figure S4), suggesting that
c-Jun stability is important for ERK-mediated effects on
c-Jun expression. To better understand the effect of
ERK on stability versus transcription of c-Jun, we moni-
tored changes in the expression of exogenously ex-
pressed c-Jun, which is not expected to reflect changes
in c-Jun transcription. As seen with the endogenous pro-
tein, inhibition of ERK activity markedly decreased the
level of exogenous c-Jun expression, which was moni-
tored using two different promoters (CMV and EF; Fig-
ure 2B). As a control, levels of exogenous ATF2 were not
affected by PD98059 (Figure 2B). These results suggest
that the MEK/ERK pathway affects c-Jun stability.
Since c-Jun degradation requires phosphorylation of
T239 by GSK3 (Wei et al., 2005), we investigated whether
ERK elicits its effect on c-Jun stability via inactivation of
GSK3. In the event that ERK inhibition destabilizes c-Jun
via GSK3 phosphorylation, LiCl (a GSK3 inhibitor) would
be expected to reverse the effect of PD98059. Indeed,
treatment of cells with LiCl attenuated PD98059’s effect,
resulting in almost complete restoration of initial c-Jun
levels (Figure 2C). Since LiCl also inhibits other protein ki-
nases with only slightly less potency than GSK3 (Davies
et al., 2000), it has been suggested that a structurally un-
related GSK3 inhibitor such as Kenpaullone should be
used in combination with LiCl to confirm a GSK3 involve-
ment (Bain et al., 2003). As shown in Figure 2D, both Ken-
paullone and LiCl partially prevented the decrease in
endogenous c-Jun levels due to PD98059, confirming
that GSK3 mediates the effects of ERK on c-Jun. The an-
tagonistic effect of GSK3 and MEK/ERK on c-Jun levels
suggests that PD98059 blocks GSK3 inactivation by
ERK. In fact, analysis performed with pGSK3 (S9/S21)
antibody revealed that the level of pGSK3 (nonactive
form) in control cells was reduced upon treatment with
PD98059 (Figure 2E). Consistent with the effect of GSK3
on regulation of c-Jun stability by ERK is the finding that
c-Jun mutated on the GSK3 phosphoacceptor site(s)
was partially (single mutants T239A and S243A) or com-
pletely (double mutant T239A/S243A) resistant to degra-
dation induced by the ERK pathway inhibitor (Figure 2F).
In its role as a GSK3 upstream kinase, Akt has been pro-
posed as a major regulator of cellular levels of c-Jun (Wei
et al., 2005). Since our data indicate that c-Jun is regulated
by ERK, we compared the relative contribution of Akt and
ERK to c-Jun levels. To this end, melanoma cells display-
ing different levels of active Akt were treated with
PD98059 and LY294002, a PI3K inhibitor, and the effect
on c-Jun expression was determined. An evident reduc-
tion in c-Jun levels upon treatment with the ERK pathway
inhibitor was observed in all five melanoma cell lines as-
sayed (Figure 2G). Interestingly, inhibition of the PI3K/
Akt pathway by LY294002 did not affect c-Jun levels in
A375, WM35, and Lu1205 cells and only slightly reduced
it in WM115 and WM9 cells (Figure 2G). Taken together,
these data indicate that constitutive ERK activation inCancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc. 449
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(A) Regulation of c-Jun by the MEK/ERK pathway is via transcriptional and post-transcriptional mechanisms. A375 cells were treated with 50 mM
PD98059 (PD) at the indicated time points in the presence or absence of Actinomycin D (Act D) (see Experimental Procedures). Protein samples
were analyzed by western blots using the indicated antibodies. a-Tubulin reveals equal loading. ns, nonspecific band. Quantification of c-Jun level
is shown. For all quantifications, c-Jun levels were normalized using a-Tubulin levels. The experiment shown is representative of the four experiments
performed.
(B) Inhibition of theMEK/ERK pathway affects the levels of exogenously expressed c-Jun. Lu1205 cells were transfectedwith either 0.5 mg Jun-HA (an
expression vector containing the EF [elongation factor] promoter) or 1 mg CMV-HA-Jun (an expression vector using a CMV promoter). ATF2-Flag
(1 mg) was used to monitor transfection efficiency. Twenty-four hours after transfection, cells were treated with 50 mM PD98059 (PD) for 8 hr. Protein
samples were analyzed by western blots using HA or Flag antibody as indicated. a-Tubulin reveals equal loading.
(C) LiCl restores c-Jun levels reduced by MEK/ERK inhibitors. Lu1205 cells were transfected with c-Jun-HA and ATF2-Flag as indicated in (B).
Twenty-four hours after transfection, cells were treated with 50 mMPD98059 (PD) in the presence or absence of 10mMLiCl for 12 hr. Protein samples
were analyzed by western blots using HA and Flag antibodies. a-Tubulin reveals equal loading.
(D) LiCl and Kenpaullone attenuate the effect of MEK/ERK inhibitors on endogenous c-Jun levels. A375 cells were treatedwith 50mMPD98059 (PD) for
12 hr in the presence or absence of 10 mM LiCl or 10 mM Kenpaullone (Ken). Protein samples were analyzed by western blots using the indicated
antibodies. a-Tubulin reveals equal loading. c-Jun protein levels were normalized to a-Tubulin levels. The experiment shown is representative of
the four experiments performed.
(E) Phosphorylation of GSK3(S9/S21) is inhibited by PD98059. A375 cells were treated with 50 mM PD98059 (PD) for 12 hr. Protein samples were
analyzed by western blots using the indicated antibodies. a-Tubulin reveals equal loading.
(F) T239 and S243 are required for regulation of c-Jun byMEK/ERK. Lu1205 cells were transfected with 0.5 mg of Flag-tagged c-JunWT, c-Jun T239A,
c-Jun S243A, or c-Jun T239A/S243A. ATF2-Flag (1 mg) was used to monitor transfection efficiency. Twenty-four hours after transfection, cells were
treated with 50 mM PD98059 for 12 hr. Protein samples were analyzed by western blots using Flag antibody. a-Tubulin reveals equal loading. Graph
shows c-Jun protein levels normalized to a-Tubulin levels. One experiment representative (of three performed) is shown.
(G) ERK regulates c-Jun levels in melanoma. The indicated melanoma cell lines were treated with 50 mM PD98059 (PD) or 10 mM LY294002 (LY) for
12 hr in the absence of serum. Protein samples were analyzed by western blots using the indicated antibodies. a-Tubulin reveals equal loading.melanoma cells is the primary pathway that regulates the
levels of c-Jun expression, in part, by inactivating GSK3
and consequently preventing c-Jun degradation.450 Cancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc.ERK Affects c-Jun Transcription via CREB
Real-time PCRanalysis of c-JunmRNA revealed amarked
inhibition of c-Jun transcription upon treatment with the
Cancer Cell
ERK-JNK Crosstalk in MelanomaFigure 3. ERK Regulates c-Jun Transcription
(A) Inhibition of the MEK/ERK pathway affects c-Jun mRNA levels. A375 cells were treated with 50 mMPD98059 for the indicated time periods. c-Jun
mRNA levels were analyzed with real-time PCR. Data were normalized using levels of b-Actin mRNA. Results are shown as the mean (bar) ± standard
deviation (SD) of the respective relative concentrations. A representative experiment (of three performed) is shown.
(B) Inhibition of the MEK/ERK pathway affects CREB phosphorylation. A375 cells were treated with 50 mM PD98059 for 12 hr. Protein samples were
analyzed by western blots using the indicated antibodies. a-Tubulin reveals equal loading.
(C) CREB siRNA affects c-Jun protein levels in melanoma. Protein extracts from A375SM cells stably transfected with nontargeting vector (NT) or with
a vector encoding CREB siRNA were analyzed by western blots using the indicated antibodies. a-Tubulin reveals equal loading.
(D) CREB siRNA affects c-Jun mRNA levels. RNA was extracted from A375SM cells stably transfected with nontargeting vector (NT) or with a vector
encoding CREB siRNA. c-JunmRNA levels were analyzed with real-time PCR. Data were normalized using levels of b-ActinmRNA. Results are shown
as the mean (bar) ± SD of the respective relative concentrations. A representative experiment (of three performed) is shown.
(E) CREB siRNA affects transcription driven by the c-Jun promoter. A375SM cells stably transfected with nontargeting vector (NT) or with a vector
encoding CREB siRNA were transiently transfected with 0.2 mMof luciferase reporter containing the c-JunWT promoter or c-Jun promoters mutated
on the Jun2 site (Jun2-M), the TRE site (TRE-M) or the double mutant. Results are shown as the mean ± SD. Data were standardized using b-galac-
tosidase activity.ERK pathway inhibitor (Figure 3A), suggesting that ERK
regulates c-Jun mRNA levels. Since c-Jun is responsible
for its own transcription (Angel et al., 1988), changes in
c-Jun activity are expected to affect c-Jun mRNA levels
as well. Therefore, we first evaluated ERK-dependent
c-Jun activation bymeasuring phosphorylation of N termi-
nus sites, Ser63 and Thr91/Thr93. This analysis revealed
that inhibition of ERK activity for 30 min does not affect
S63 (Figure S5) and Thr91/Thr93 (Figure S6) phosphoryla-
tion. In contrast, phosphorylation of Ser63 and Thr91/
Thr93 was reduced by addition of a JNK inhibitor (Figures
S5 and S6; note that within 30min, the time frame used for
this analysis, c-Jun levels are not affected). These datasuggest that ERK is not directly involved in c-Jun phos-
phorylation and activation. Consistent with this possibility,
the levels of exogenousWT and S63A forms of c-Jun were
affected to the same degree upon inhibition of ERK
(Figure S7). An alternative explanation for ERK-dependent
changes in c-Jun transcription is that this process is me-
diated by other transcription factor(s) downstream of
ERK. Among the possible transcription factors that could
mediate ERK-dependent c-Jun transcription is ATF1
(Gupta and Prywes, 2002). Inhibition of ATF1 expression
by its corresponding siRNAdidnot affect c-Junexpression
(Figure S8), suggesting that ATF1 is not involved in regula-
tion of c-Jun transcription in melanoma cells. We nextCancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc. 451
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factor activated by ERK (Wiggin et al., 2002; Johannessen
et al., 2004) that could potentially affect AP1/CRE ele-
ments known to be important in c-Jun transcription.
Thus, we tested the effect of the ERK inhibitor on CREB
phosphorylation. CREB phosphorylation on S133, which
is required for its transcriptional activities, was efficiently
inhibited by PD98059 (Figure 3B), indicating positive regu-
lation by ERK. Moreover, inhibition of CREB expression
by siRNA markedly decreased c-Jun expression at both
the protein (Figure 3C) and mRNA (Figure 3D) levels. Addi-
tionally, a dominant-negative mutant of CREB (A-CREB)
also reduced c-Jun protein levels (Figure S9). In line with
these results,CREBsiRNA inhibited transcriptional activity
driven by the c-Jun promoter (Figure 3E). These findings
reveal that in melanoma, ERK controls c-Jun RNA expres-
sion levels via its activation of CREB.
c-Jun Is Required for RACK1 Expression
Increased c-Jun expression by ERK is expected to con-
tribute to its transcriptional activities. Yet for c-Jun to func-
tion as a potent transcription factor, phosphorylation on
Ser63 and Ser73 is required, which inmelanoma is primar-
ily mediated by JNK (Figures S5 and S6). Since both PKC
and JNK are constitutively active in most melanoma cell
lines (Figure 1A), one would expect that ERK contributions
to c-Jun expression will be complemented by c-Jun phos-
phorylation by JNK, with a possible contribution of PKC.
To test this possibility, we inhibited PKC activity with
a pharmacological inhibitor. Consistent with our earlier
report on the role of PKC in activation of JNK and c-Jun
in melanoma cells, inhibition of PKC by Go6976 or a dom-
inant-negative form of PKCb markedly decreased basal
phosphorylation of JNK1 and JNK2 in melanoma cell lines
A375 and Lu1205 (Figure 4A; Figure S10) and lowered
c-Jun transcriptional activity, assessed using a TRE-Luc
reporter assay (Figure 4B). TPA, which induces PKC at
an early time point and downregulates it later, increased
RACK1 expression in a manner that coincided with JNK
activity (Figure S11). This observation prompted us to ex-
amine possible changes in RACK1 transcription following
inhibition of PKC and JNK activity. Significantly, incuba-
tion with Go6976 inhibited the luciferase activity driven
by the RACK1 promoter, similar to what was seen for
the TRE promoter (Figure 4B). Inhibition of PKC did not
affect transcriptional activity driven by a b-catenin-Luc
reporter plasmid, used here as a control (Figure 4B, top).
This observation implies that RACK1 transcription may
be dependent on c-Jun.
To directly address the possible role of c-Jun in RACK1
expression, we used cells deficient in c-Jun or in which
c-Jun transcriptional activities were effectively inhibited
by a dominant-negative c-Jun construct (TAM67). Inhibi-
tion of c-Jun transcriptional activities or the lack of c-Jun
expression sufficed to attenuate RACK1, at both protein
(Figures 4C and 4D) and mRNA levels (Figure 4E). Consis-
tent with the mRNA data, luciferase activity driven by
the RACK1 promoter was also reduced in both TAM67-
expressing cells and in fibroblasts that lack c-Jun (Fig-452 Cancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc.ure 4F). Moreover, cells in which activated c-Jun was
reduced by using JNK siRNA also revealed lower levels
of RACK1 (Figure S12). To further substantiate the contri-
bution of JNK/c-Jun signaling to RACK1 expression, we
monitored changes in RACK1 expression in cells trans-
fected with the constitutively active form of MEKK1
(DMEKK1), which is known to elicit strong activation of
JNK and c-Jun. As shown in Figure 4G, DMEKK1 effi-
ciently increased activation of c-Jun and elevated the level
of RACK1 expression. Similarly, DMEKK1 expression also
increased the level of RACK1-driven luciferase activity
(Figure 4H). Together, these data indicate that JNK signal-
ing, via c-Jun, is a positive regulator of RACK1 expression.
Mapping the AP-1 Site on the RACK1 Promoter
We next mapped the c-Jun response element(s) on the
RACK1 promoter. Analysis of the proximal region revealed
the presence of c-Jun target sequences at positions
1814, 863, 733, and 60; another possible site was
found at +517 in the first intron (marked with letters A–E
in Figure 5A). Nested deletions of the RACK1 promoter
containing these elements were cloned into a luciferase
promoterless vector, and the degree of luciferase activity
was monitored along with the effect of PKC inhibitor
Go6976. This analysis identified the AP-1 site at position
60 (TGAATCA) as sufficient to mediate PKC/JNK-
dependent activation of the RACK1 promoter (Figure 5B).
Gel-shift analysis demonstrated the ability of c-Jun to
bind to an oligonucleotide containing the AP-1 site (Fig-
ure 5C; Figure S13). Consistent with this finding, mutation
within this site attenuated the basal level of reporter activ-
ity (Figure 5D) and the binding of c-Jun (Figure 5C), con-
firming that c-Jun regulates RACK1 transcription via its re-
sponse element at the 60 site. Further support for the
role of c-Jun in regulation of RACK1 transcription comes
from ChIP analysis. Sheared chromatin was immunopre-
cipitated with antibodies to c-Jun (or control IgG) followed
by PCR amplification of RACK1 promoter sequences
bearing the AP1 response element. Immunoprecipitation
of c-Jun enabled amplification of RACK1 promoter se-
quences (Figure 5E), demonstrating in vivo binding of
c-Jun to the RACK1 promoter. Amplification of RACK1
promoter sequences was not observed in cells expressing
TAM67 (Figure 5E) or upon transfection of siRNA against
c-Jun (Figure 5F) and decreased following treatment
with PD98059 (Figure 5G). These data substantiates the
finding that c-Jun mediates RACK1 transcription.
Earlier studies demonstrated that RACK1 is required for
PKC signaling (Schechtman and Mochly-Rosen, 2001) as
well as for PKC-dependent activation of JNK (Lopez-
Bergami et al., 2005a; Liu et al., 2006). In accordance with
these data, inhibition of RACK1 expression by a specific
siRNA attenuated JNK activation (Lopez-Bergami et al.,
2005a) and c-Jun phosphorylation (Figure S14). Taken
together, our data suggest that c-Jun is part of a feed-
forward loop mechanism that maintains high levels of
RACK1 expression to support PKC-dependent JNK acti-
vation of c-Jun. Constitutive activation of c-Jun is ex-
pected to contribute to its oncogenic potential.
Cancer Cell
ERK-JNK Crosstalk in MelanomaFigure 4. c-Jun Regulates RACK1 Transcription
(A) Go6976 inhibits JNK activation. A375 cells were treated with Go6976 for 2 hr before protein extracts were prepared. Levels of P-JNK and total JNK
were assessed by Western blot. b-actin was used to monitor equal loading.
(B) Inhibition of PKC reduces RACK1-driven luciferase activity. The luciferase activity driven by the RACK1 promoter (2 Kb of the proximal RACK1
promoter cloned into a pGL2 vector) was assessed in Lu1205 cells in the presence of Go6976 (3 mM for 8 hr). TRE and TOP vectors were used as
positive and negative controls, respectively. Results are shown as the mean ± SD. Data were standardized on the basis of b-galactosidase activity.
(C) c-Jun regulates RACK1 expression. Protein extracts from SW1 cells stably transfected with FLAG-TAM67 were blotted with RACK1 and FLAG
antibodies. b-actin antibody was used to monitor equal protein loading.
(D) RACK1 expression is reduced in c-Jun/ fibroblasts. Protein extracts from c-Jun/ and control fibroblasts were blotted with RACK1 antibody.
b-actin and a-tubulin antibodies were used to monitor equal protein loading.
(E) Decrease in relative mRNAs levels of RACK1 in c-Jun/MEF and in SW1-TAM67 cells. Relative levels of RACK1 mRNA were determined by real-
time quantitative PCR. Reactions were run in triplicate. b-actin was used as a control. Results are shown as the mean (bar) ± SD of the respective
relative concentrations. A representative experiment (of three performed) is shown.
(F) c-Jun regulates RACK1-driven transcription. The luciferase activity driven by the RACK1 promoter (2Kb of the proximal RACK1 promoter cloned
into a pGL2 vector) was assessed in SW1 cells expressing TAM67 as well as inWT and c-Junmutant fibroblasts. Results are shown as themean ± SD.
Data were standardized on the basis of b-gal activity.
(G) Activation of the JNK/c-Jun pathway increases RACK1 expression. HEK293T cells were transfected with DMEKK1 or empty pEF plasmid. Protein
extracts were obtained 48 hr posttransfection and blotted with the indicated antibodies. b-actin antibody was used to monitor loading. Arrow
indicates the position of DMEKK1.
(H) DMEKK1 increases RACK1-driven transcription. The luciferase activity driven by the RACK1 promoter (2 Kb of the proximal RACK1 promoter
cloned into a pGL2 vector) was assessed in HEK293T cells transfected with DMEKK1. Results are shown as the mean ± SD. Data were standardized
on the basis of b-gal activity.ERK Increases JNK Activity via the RACK1/PKC/
JNK/c-Jun Feedback Loop
The data above showed that c-Jun levels in melanoma are
controlled by constitutive ERK activity. In turn, c-Jun in-
duces expression of RACK1, which is required for JNK
activation by PKC, pointing to a c-Jun/RACK1/PKC/JNK
feedback loop. Accordingly, interference with the MEK/
ERK pathway is expected to attenuate the effect of ERK
on JNK activity. To test this possibility, ERK and JNK
inhibitors were compared with regard to their effect on
c-Jun expression levels. Whereas short exposure to an
ERK inhibitor did not affect c-Jun expression in A375 mel-
anoma cells, longer treatment blocked c-Jun expression(Figure 6A) and reduced RACK1 expression and JNK
activity (Figure 6A). Interestingly, treatment with a JNK in-
hibitor also decreased c-Jun levels although with slower
kinetics compared with PD98059. Similarly, analysis of
four melanoma cell lines treated with PD98059 for 16 hr
showed a decrease in c-Jun levels with a concomitant de-
crease in P-JNK levels (Figure 6B). Consistent with these
findings, immunokinase reactions using JNK immunopuri-
fied from melanoma cells subjected to treatment with the
ERK inhibitor revealed a 4-fold decrease in JNK activ-
ity (Figure S15). Furthermore, constitutive expression of
the dominant-negative c-Jun construct, TAM67, in SW1
melanoma cells attenuated the degree of JNK activity,Cancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc. 453
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ERK-JNK Crosstalk in MelanomaFigure 5. Mapping the c-Jun Response Element on the RACK1 Promoter
(A) Structure of the RACK1 promoter. Putative c-Jun response elements and fragments of the promoter that were cloned are depicted (black boxes,
‘‘A’’–‘‘E’’).
(B) Mapping of the functional AP-1 site of the mouse RACK1 promoter. DNA fragments containing various response elements (A) were cloned into
pGL2 and their luciferase activity was assayed in Lu1205 cells in the presence of Go6976 (3 mM for 8 hr). TOP vector was used as negative control.
Results are shown as the mean ± SD.
(C) c-Jun binds to the AP-1 element located at 60 on the RACK1 promoter. Ten micrograms of nuclear extracts from control cells were incubated
with a double-strandedDNA fragment probe corresponding to the67 to54 region of the RACK1 promoter carrying a single AP-1motif (lanes 4–12).
Unlabeled competitors (RACK1, WT oligonucleotide (lane 5), RACK1-M, RACK1 oligonucleotide containing two bp changes in the AP-1 element
(lane 6) and LRP6, nonrelated competitor (lane 7) were added at a 10-fold excess as indicated (lanes 5 and 7 were run in duplicates). For supershift
assays, 0.4 (lanes 8 and 10) or 2 mg (lanes 9 and 11) of c-Jun Ab or control IgG (Santa Cruz Biotechnology, Santa Cruz, CA) were included in the re-
action. Lanes 4 and 12 show the shift in the absence of antibodies or competitors. The lower arrow (A) indicates a specific retarded band correspond-
ing to c-Jun in complex with the probe. The upper arrow (B) indicates the supershifted complex. Reactions using nuclear extracts from c-Jun siRNA
treated cells were included as a control (lane 2 and 3, 20, and 10 mg respectively). The lower panel shows changes in c-Jun protein levels in cells
transfected with control (sc) and c-Jun siRNA. A picture of the complete gel is shown in Figure S13.
(D) Mutation of c-Jun element at60 inhibits reporter activity. The AP-1 response element D wasmutated and the relative luciferase activity of theWT
and mutant construct was assessed in Lu1205 cells. Results are shown as the mean ± SD. Data were standardized on the basis of b-galactosidase
activity.
(E) Chromatin immunoprecipitation assay. Sheared chromatin from SW1 cells or SW1 stably transfected with TAM67 was immunoprecipitated with
appropriate antibody (anti-c-Jun or control IgG). Immunoprecipitated DNA was used as the template in PCR using primers corresponding to the
proximal region of the RACK1 promoter. GAPDH primers were used as control.
(F) c-Jun is not present at the RACK1 promoter in cells treated with c-Jun siRNA. Sheared chromatin from SW1 cells or SW1 transfected with c-Jun
siRNA was immunoprecipitated with appropriate antibody (anti-c-Jun or control IgG). Samples were processed as in Figure 5E.
(G) MEK inhibitor affects c-Jun binding to RACK1 promoter. Sheared chromatin from SW1 cells or SW1 treated with 50 mM PD98059 (PD) in the
presence or absence of 10 mM LiCl was immunoprecipitated with appropriate antibody (anti-c-Jun or control IgG). Samples were processed as
in Figure 5E.454 Cancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc.
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ERK-JNK Crosstalk in MelanomaFigure 6. ERK Induces JNK Activation as Part of Crosstalk and Feed-Forward Mechanisms
(A) Inhibition of the MEK/ERK pathway affects RACK1 and P-JNK levels. A375 cells were treated with 50 mM PD98059 (PD) or 10 mM of JNK inhibitor
for the indicated times. Protein samples were analyzed by western blots using the indicated antibodies. a-Tubulin reveals equal loading.
(B) Inhibition of theMEK/ERK pathway affects c-Jun, P-JNK and cyclin D1 levels. The indicatedmelanoma cell lines were treatedwith 50 mMPD98059
for 16 hr. Protein samples were analyzed by western blots using the indicated antibodies. a-Tubulin reveals equal loading.
(C) Inhibition of c-Jun attenuates JNK activity in SW1 mouse melanoma cells. SW1 cells were transfected to establish stable clones expressing the
dominant-negative form of c-Jun, TAM67. Cells were used to monitor JNK phosphorylation on aa 183/5, which reflect JNK activity.
(D) c-Jun regulates cyclin D1 expression. Protein extracts from Lu1205 and SW1 cells stably transfected with FLAG-TAM67 were blotted with the
indicated antibodies. a-Tubulin antibody was used to monitor equal protein loading.
(E) LiCl restores c-Jun and cyclin D1 levels that are reduced by MEK/ERK inhibitors. Lu1205 cells were treated with 50 mM PD98059 (PD) in the
presence or absence of 10mM LiCl for 12 hr. Protein samples were analyzed by western blots using the indicated antibodies. a-Tubulin reveals equal
loading.
(F) CREB siRNA affects both c-Jun and cyclin D1 protein levels in melanoma. Protein extracts from A375SM cells stably transfected with nontargeting
vector (NT) or with a vector encoding CREB siRNA were analyzed by Western blots using the indicated antibodies. a-Tubulin reveals equal loading.substantiating the role of c-Jun in JNK activity (Figure 6C).
All in all, our results establish that regulation of c-Jun by
ERK ultimately affects JNK in melanoma.
c-Jun Activation by ERK and JNK Induces Cyclin
D1 Transcription
c-Jun expression and phosphorylation by ERK and JNK
are expected to result in a constitutively transcriptionally
active c-Jun. To test this possibility, we assessed the roles
of ERK and JNK in relation to the c-Jun transcriptional tar-
get, cyclin D1 (Sabbah et al., 1999), which is frequently
overexpressed in melanoma (Bartek et al., 1993; Mae-
landsmo et al., 1996; Pardo et al., 2004; Sauter et al.,
2002). Inhibition of c-Jun activity by TAM67 efficiently at-
tenuated expression of cyclin D1 in human and mouse
melanoma cells (Figure 6D), confirming its primary role inregulation of cyclin D1 expression. Similarly, inhibition of
ERK activity in four humanmelanoma cell lines attenuated
the level of cyclin D1 expression (Figure 6B). In line with
our model indicating that ERK regulates c-Jun via GSK3
and CREB, inhibition of GSK3 attenuated the effect of
ERK inhibitor on c-Jun and cyclin D1 expression (Fig-
ure 6E), and siRNA of CREB reduced c-Jun and cyclin D1
expression (Figure 6F).
ERK Activity Associates with JNK, Jun, and RACK1
Levels and Activity in Human Tumor Samples
To substantiate a causative link between the ERK and JNK
signaling pathways, we analyzed levels of active ERK and
JNK and expression levels of c-Jun, cyclin D1, and RACK1
in a set of 24 melanoma tumors (Figure 7A). Bcl-2 expres-
sion was assessed as outlier in statistical analysis. Of theCancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc. 455
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ERK-JNK Crosstalk in MelanomaFigure 7. Analysis of RACK1, c-Jun, Cyclin D, P-ERK, and P-JNK Levels in Melanoma Tumor Samples
(A) ERK activity is associated with JNK, c-Jun and RACK1 levels and activity in human tumor samples. Protein samples (80 mg) obtained from
melanoma tumors were analyzed by Western blot using the indicated antibodies. For the RACK1, Bcl-2, and a-Tubulin blots, 20 mg of protein was
used. The status of BRAF and NRAS genes is shown above the tumor ID. RAS indicates a Q61K or Q61R mutation. RAF indicates a V599E mutation.
WT indicates the absence of Q61 and V599 mutation in NRAS or BRAF.
(B) Stack graph represents relative levels of P-ERK, c-Jun, RACK1 and P-JNK that were quantified (Figure S16) and converted into numbers (0, 1, 2, 3)
to reflect protein expression level qualitatively.
(C) Hierarchical clustering of the samples shown in (A) was performed with the aid of HCE program (Seo and Shneiderman, 2002), using average
linkage and Euclidean distance measure between expression levels. Different expression levels are shown in different colors: 0, light green; 1, green;
2, black; and 3, red. The order of linking corresponds to the proximity of expression levels in different cell types. Minimal similarity values (computed in
HCE program using Euclidean distance and normalized to a scale from 0 [no similarity] to 1 [identical profile]) are shown on the tree to reflect
qualitatively similarities in expression patterns. The analysis revealed significant relations between P-ERK and c-Jun (0.672), c-Jun and RACK1
(0.617) and between P-ERK and RACK1 (0.680) levels. These values are significant with 99% confidence (the critical value for 1% significance level
for 22 degrees of freedom (242) is 0.515, using Student’s t statistics). Bcl2 levels, which are not directly associated with the other proteins in this
analysis, served as an outlier for the statistical analysis.24 melanoma samples, 16 were found to exhibit a robust
P-ERK staining (66%). Of these, 13 (81%) presented high
levels of c-Jun (Figure 7A; Figure S16). Of the remaining 8
samples, which showed negative or very weak P-ERK
staining, none displayed high c-Jun levels (Figure 7A; Fig-
ures S16 and S17). This finding provides important sup-
port for the link between ERK and c-Jun, as revealed in
the present studies. Furthermore, as our data also point
to a possible cooperation between ERK and JNK that
would result in high levels of transcriptionally active c-Jun,456 Cancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc.we assessed the possible relationship between ERK and
JNK activities and c-Jun and RACK1 expression levels
in the melanoma tumor set. Twelve of the 24 samples
(50%) were found to exhibit positive staining for both
P-ERK and P-JNK together with high levels of c-Jun. Of
those, 11 (92%) also exhibited high levels of RACK1
(Figure 7A; Figure S16), substantiating the link among
P-ERK, P-JNK, c-Jun, and RACK1 pointed out in the pres-
ent study. Interestingly, of the remaining 12 samples (sam-
ples that showed either negative P-ERK or negative
Cancer Cell
ERK-JNK Crosstalk in MelanomaP-JNK), only 3 exhibited high levels of RACK1, suggesting
that possibly another mechanism upregulates RACK1 ex-
pression in a small fraction of samples of this tumor type.
Relative levels of P-ERK, c-Jun, RACK1, and P-JNK are
represented in a stacked graph, which reveals the trend of
the contribution of each of the above five variables over
different samples (Figure 7B). These data clearly reveal
positive correlation between the four variables, substanti-
ating the relationship between P-ERK-c-Jun-RACK1 and
P-JNK (Figure 7C). This analysis provides strong support
for rewiring between the ERK and JNK signaling pathways
identified in human melanoma.
Of note, some tumor samples that harbor mutations on
eitherBRAF orNRAS showed negative or very weak stain-
ing of P-ERK that correlated with negative or weak P-MEK
staining (Figure 7A and data not shown).
As shown for themelanoma cell lines tested, the link be-
tween ERK and c-Jun expression and activity affects
RACK1 as well as Cyclin D1 expression. Consistent with
the notion that in a certain percentage of melanoma
tumors cyclin D1 is upregulated as a result of gene ampli-
fication, melanoma samples exhibited elevated expres-
sion of cyclin D1, or cyclin D2, regardless of the status
of P-ERK or c-Jun. The latter finding reveals that both tran-
scriptional upregulation and gene amplification increase
cyclin D1 in melanoma tumors.
DISCUSSION
Understanding mechanisms underlying crosstalk among
signal transductionpathways is key tounveiling thedynam-
ics of multidimensional regulatory signaling networks. Al-
thoughsuchnetworks fine-tune cellular functionunder nor-
mal growth as well as following stress and DNA damage, it
has been a challenge to understand the nature of changes
in this complex mechanism that occur in pathological
cases, including human cancer. Melanoma, an aggressive
form of skin cancer that often harbors mutant BRAF or
NRAS, and consequently increased ERK-MAPK activity,
serves as a paradigm of rewiring signaling pathways.
Here, we provide a blueprint for a rewired signaling
pathway in melanoma. Our data reveal that ERK increases
the level of c-Jun expression by affecting its transcription
and stability. We further demonstrate that c-Jun increases
the transcription of RACK1, an adaptor protein required
for activation of JNK by PKC, which constitutes a feed-for-
ward mechanism that increases c-Jun transcriptional ac-
tivity. Lastly, we demonstrate that the ERK-Jun signaling
cascade is required for c-Jun-mediated transcription of
cyclin D1, which is often found to be overexpressed in hu-
man melanomas. Analysis of melanoma tumors confirms
the changes in these signaling pathways, for which our
studies provide the underlying mechanisms.
Our study identifies the mechanisms underlying upre-
gulation of c-Jun expression by ERK, as we demonstrate
the effect of ERK on GSK3 inactivation, resulting in c-Jun
protein stabilization, and on CREB activation, which in-
creases c-Jun transcription (model proposed in Figure 8).
Activation of ERK results in phosphorylation of CREB atSer133, either directly by ERK or by ERK-stimulated
MSK (Wiggin et al., 2002). The finding that ERK contrib-
utes to stabilization of c-Jun through inactivation of
GSK3 is consistent with those reported by Wei et al.
(2005), who demonstrated that phosphorylation of c-Jun
on T239 by GSK3b is critical in c-Jun degradation. Yet,
whereas Akt was shown to affect GSK3b phosphorylation
in HeLa cells (Wei et al., 2005), inmelanoma cells, ERK sig-
naling was found to mediate primarily GSK3 phosphory-
lation, resulting in c-Jun stabilization. ERK-dependent
GSK3 phosphorylation at S9/S21 is likely to be mediated
by an intermediate kinase, although we have ruled out
RSK (siRNA of RSK did not impact c-Jun stability in these
cells; data not shown). Alternatively, association of ERK
with GSK3 and subsequent phosphorylation of GSK3 at
T43 was shown to enhance the rate of phosphorylation
on Ser9 by a third kinase (Ding et al., 2005).
Our data identify RACK1 as a c-Jun transcriptional
target. It is plausible that other c-Jun target genes may
contribute to the feed-forward loop mechanism. Among
those are PDK1, the PKC upstream kinase, whose tran-
scription also appears to be c-Jun-dependent (P.L.-B.,
Z.R., unpublished data) and c-Jun-dependent changes
in expression of protein phosphatases that affect JNK
activity (Sprowles et al., 2005).
Several requirements must be satisfied for the feed-
forward loop to exist. First is that c-Jun is also subjected
to phosphorylation on residues S63 and S73 (and possibly
T91 and T93), thus acquiring its transcriptional capabil-
ities. Such phosphorylation is primarily attributed to
JNK, although it has been also ascribed to ERK in JNK-
deficient cells (Morton et al., 2003); our data rule out
ERK involvement in this process in melanoma (Figures
S5 and S6), further substantiating the need for the
Figure 8. Model of ERK Crosstalk with JNK Signaling
Superactive ERK, as seen in melanomas that carry mutant B-RAF or
N-RAS genes, increases stability of c-Jun via its phosphorylation-
dependent inactivation of GSK3, and induces c-Jun transcription via
its activation of CREB. In turn, c-Jun induces transcription of RACK1,
which, in concert with active PKC andMKK4/7, augment the degree of
JNK activity to further increase (andmaintain) c-Jun stability and activ-
ity, constituting a feed-forward loop mechanism induced by ERK. Our
data support the existence of this model in melanoma, but not in cells
in which ERK activity is not sufficiently high.Cancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc. 457
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JNK-PKC module. The second requirement is that JNK
must be activated by the canonical MKK4/7 pathway.
This requirement is crucial since the contribution of PKC
to overall JNK activity depends on JNK’s own phosphor-
ylation on amino acids 183/5 by MKK4/7. Since active
JNK is commonly seen inmelanoma (Figure 1A; Figure 7A;
Lopez-Bergami et al., 2005b), this requirement is satisfied,
although the reason for the upregulation of JNK in mela-
noma is not completely clear. The finding that some tumor
samples display positive P-JNK staining in the absence of
ERK activity suggests that JNK activation proceeds
through ERK-independent mechanisms. In any case, in
agreement with our model, JNK activity by itself is not suf-
ficient to maintain high levels of c-Jun. The third require-
ment relates to PKC’s own activity. To cooperate with
RACK1 in augmenting JNK activity, PKC must be active.
Earlier studies pointed out that expression of several
PKC isoforms is elevated in melanoma (Oka and Kikkawa,
2005; Selzer et al., 2002). Herewedemonstrate that PKCa/
b are among the isoforms that appear to be predominantly
active in melanoma (Figure 1A; Figure S17). That PKC is
important for growth and metastasis of melanoma was
shown in studies where pharmacological inhibitors of
PKC effectively inhibited growth of melanoma in mouse
xenograft models (Dumont et al., 1992; Mapelli et al., 1994).
That PKC and JNK are active in this tumor type satisfies
the above-stated requirements and supports the exis-
tence of the feed-forward loop mechanism triggered by
ERK’s effect on c-Jun expression levels (Figure 8).
The cell lines we used were obtained, for the most part,
from vertical growth phase tumors (A375, WM115,
Lu1205, WM9), which are associated with more meta-
static phenotypes. Consistent with our findings, CREB ac-
tivity was implicated in melanoma growth and metastasis
(reviewed in Nyormoi and Bar-Eli, 2003). Similarly, via its
heterodimerization with ATF2, c-Jun was also shown to
play an important role in melanoma growth (Bhoumik
et al., 2004). Importantly, regulation of c-Jun by the ERK
pathway was not seen in cells that lack constitutively
high levels of ERK activity (e.g., melanocytes or HEK293
cells), suggesting that this regulation reflects selective re-
wiring of melanoma tumors in which upstream MAPK are
constitutively active.
It is likely that our finding extends beyond the cases of
mutant B-RAF and N-RAS since activation of the MEK/
ERK pathway and upregulation of cyclin D1 are also
seen in tumors where such mutations do not exist. Thus,
one would expect that the newly established link between
ERK and JNK, with its implications regarding cyclin D1 ex-
pression, may allow identifying additional deregulated sig-
naling components along the JNK or ERK signaling path-
ways. One would also expect that the link between ERK
and JNK would also exist in other tumors where ERK is
upregulated, a common occurrence in human cancer
(Davies et al., 2002; Downward, 2003).
The effect of ERK on both transcriptional activation and
stabilization of c-Jun via CREB activation and GSK3 inac-
tivation, respectively, points to the importance of securing458 Cancer Cell 11, 447–460, May 2007 ª2007 Elsevier Inc.high levels of c-Jun expression, as illustrated in mela-
noma-derived cells. The fact that two pathways cooperate
in increasing c-Jun expression levels reflects independent
mechanisms whose impact on c-Jun expression might in-
volve different kinetics and possibly magnitudes (Murphy
and Blenis, 2006). This consideration may be important
in fine-tuning the degree of inhibition of ERK activity in
melanomas where ERK is among the primary targets of
therapy.
In summary, the study presented here provides an
undisclosed insight into the mechanism underlying the
link between the ERK and JNK pathways that is mediated
by ERK’s effect on c-Jun expression levels. This rewiring
has been demonstrated in human melanoma, where mu-
tant NRAS or BRAF affect downstream ERK signaling. In
providing an initial blueprint for rewiring key signal trans-
duction pathways in melanoma, our findings point to addi-
tional targets for therapy of this tumor type.
EXPERIMENTAL PROCEDURES
Melanoma Samples and Cell Lines
Melanoma samples were obtained in the operating room and were
snap frozen in liquid nitrogen within 5 min of harvest. The tumor sam-
ples were stored in liquid nitrogen until processed. All human tumor
samples were collected by The Tissue Retrieval Service, a shared re-
source of The Cancer Institute of New Jersey, following UMDNJ-RWJ
Medical School IRB and HIPPA guidelines. All patients signed in-
formed consent for the harvesting, storage, and subsequent use of
their tissue samples in research-related projects. All specimens were
encoded so that no patient-identifying data is available as per IRB
and HIPPA regulations. Samples were obtained from regional dermal
metastases, nodal metastases, or distant sites of metastases. The sta-
tus of BRAF (V599E) and NRAS genes was assessed as described
(Alsina et al., 2003; Goydos et al., 2005). Activation of the MEK/ERK
pathway was confirmed by Western blot using P-ERK and P-MEK an-
tibodies. Tumors that showed no correlation of P-ERK and P-MEK
staining were not considered in our analysis. Melanoma cell lines
were kindly provided by Dr. M. Herlyn and maintained as indicated
(Satyamoorthy et al., 1997). Melanoma cell lines A375, Lu1205, and
WM9 present the V599E mutation on the BRAF gene (Satyamoorthy
et al., 2003). The WM115 cell line presents a V599D mutation on
BRAF (Tanami et al., 2004). The WM35 cell line is WT for both Ras
and BRAF (exons 11 and 15) but presents positive P-ERK staining
due to an autocrine loop (Li et al., 2003; Satyamoorthy et al., 2003).
c-Jun mutant fibroblasts were kindly provided by R. Wisdom. Cells
were transfected with calcium phosphate or by using LipofectAMINE
PLUS Reagent (Invitrogene) following the manufacturer’s protocol.
Constructs
Constructs encoding GST-Jun1–89, MEKK, and Flag-TAM67 were pre-
viously described (Bhoumik et al., 2004; Lopez-Bergami et al., 2005a).
The plasmids encoding c-Jun-Flag and c-Jun mutants were kindly
provided by W. Kaelin. The A-CREB construct (Ahn et al., 1998) was
kindly provided by C. Vinson. Fragments from the mouse RACK1 pro-
moter were cloned from the BAC clone RP23-14F5 by PCR into the
KpnI-XhoI sites of the pGL2-basic luciferase reporter (Promega). DNA
sequences were confirmed by DNA sequencing. Mutation on the
RACK1promoterwas introducedusing theQuickChangeSite-Directed
Mutagenesis Kit (Stratagene) and confirmed by DNA sequencing.
In Vitro Kinase Assay
JNK immunokinase assays were performed as described (Lopez-
Bergami et al., 2005a). Briefly, proteinswere extracted, immunoprecip-
itated with anti-JNK1 Ab and subjected to an in vitro kinase assay
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on SDS–PAGE and transferred to a nitrocellulose membrane and the
phosphorylation state of GST-Jun1–89 detected and quantified using
a phosphorimager. The same membranes were used for immu-
noblotting with anti-JNK antibodies and for Ponceau S staining of
GST-Jun1–89.
RNA Interference
Control, c-Jun-, RACK1-, and ATF1-specific siRNA oligonucleotides
were obtained from Ambion. CREB siRNA sequence GAGAGAG
GTCCGTCTAAGTT was cloned into pRSUPER and used to generate
melanoma cells that stably express this siRNA.
Cell-Cycle Analysis
Cell cycle distribution was assessed by propidium iodide staining as
described (Ivanov et al., 2001).
Additional Experimental Procedures
Antibodies and reagents, immunoblotting and immunohistochemistry,
luciferase assays, real-time PCR, chromatin immunoprecipitation, and
electrophoretic mobility shift assays are detailed in the Supplemental
Data.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures and 17 supplemental figures and can be found with this article
online at http://www.cancercell.org/cgi/content/full/11/5/447/DC1/.
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